Technology | April 09, 2026
Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
Subscribe To Our Newsletter & Stay Updated
